Targeting polymyxin-resistant Gram-negative superbugs: development of novel antimicrobial lipopeptides

革兰氏阴性“超级细菌”对抗生素的耐药性是一个重大的全球医学挑战，美国传染病协会的“坏虫子，没有药物”运动强调了这一点。在目前针对这些危险病原体的药物开发管道中，几乎没有新的抗生素。在这个项目中，新的脂肽将被设计，合成和评估对这些“超级细菌”。所获得的信息对于进一步的药物开发至关重要。

Prevalence of resistance to antibiotics among Gram-negative 'superbugs' is a major global medical challenge, which is highlighted by the Bad Bugs, No Drugs campaign of the Infectious Diseases Society of America. There are virtually no new antibiotics in the current drug development pipeline for these dangerous pathogens. In this project, novel lipopeptides will be designed, synthesised and evaluated against these 'superbugs'. Information obtained will be crucial for further drug development.